CoChat

Preexisting Antiadenoviral Immunity Is Not a Barrier to Efficient and Stable Transduction of the Brain, Mediated by Novel High-Capacity Adenovirus Vectors

Thomas, C.E., Schiedner, G., Kochanek, S., Castro, M.G., Lowenstein, P.R. · 2001 · Human Gene Therapy
Cited by 99

The DOI matches its Crossref record.

Abstract

The utility of first-generation adenovirus vectors for long-term gene transfer in humans is limited by preexisting antiadenoviral immunity. We demonstrate here that new-generation high-capacity adenovirus vectors (HC-Ads) can efficiently transduce the brain and mediate stable transgene expression for at least 2 months, even in the presence of a preexisting antiadenoviral immune response. First-generation vector-mediated transduction was almost completely abolished in preimmunized animals within 60 days of the vector injection. Levels of HC-Ad-mediated transduction by 3 days postinjection were not significantly affected by preimmunization, were reduced within 14 days to 56% of those levels seen in nonimmunized animals, and remained stable until day 60 postinjection. Acute brain inflammation elicited by the HC-Ad vector injection was more transient, and was reduced in intensity compared with brain inflammation elicited by the first-generation vector injection in immunized animals. Inflammation was significantly higher in all immunized animals than in nonimmunized animals. Our results show that preexisting antiadenoviral immunity does not significantly reduce initial HC-Ad-mediated infection of the brain and is not a barrier to stable HC-Ad vector-mediated transduction of the CNS. Although input HC-Ad capsid proteins injected into the brain may contain transient targets for a brain-infiltrating cellular adenovirus-specific immune response, this fails to eliminate transgene expression. Thus HC-Ads show promise for gene therapy of chronic brain disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/104303401750148829

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 99

Metadata

Authors
Thomas, C. E., Schiedner, G., Kochanek, S., Castro, M. G., & Lowenstein, P. R.
Venue
Human Gene Therapy
Published
2001-05
Volume
12
Issue
7
Pages
839-846
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2174973932
Cited by
99
References
0
FWCI
5.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preexisting Antiadenoviral Immunity Is Not a Barrier to Efficient and Stable Transduction of the Brain, Mediated by Novel High-Capacity Adenovirus Vectors. https://app.cochat.ai/papers/10.1089/104303401750148829
The paper
Thomas, C. E., Schiedner, G., Kochanek, S., Castro, M. G., & Lowenstein, P. R. (2001). Preexisting Antiadenoviral Immunity Is Not a Barrier to Efficient and Stable Transduction of the Brain, Mediated by Novel High-Capacity Adenovirus Vectors. Human Gene Therapy. https://doi.org/10.1089/104303401750148829

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.